Abstract
Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and indirectly through criminal activity, absenteeism and lost productivity. Opioid agonist medications, such as methadone and buprenorphine, that stabilize neuronal systems and provide narcotic blockade are the most effective treatments. Prolonged provision of these medications, defined as maintenance treatment, typically produces improved outcomes when compared with short-duration tapers and withdrawal. The benefits of opioid agonist maintenance include decreased illicit drug use, improved retention in treatment, decreased HIV risk behaviours and decreased criminal behaviour. While regulations vary by country, these medications are becoming increasingly available internationally, especially in regions experiencing rapid transmission of HIV due to injection drug use. In this review, we describe the rationale for maintenance treatment of opioid dependence, discuss emerging uses of opioid antagonists such as naltrexone and sustained-release formulations of naltrexone and buprenorphine, and provide a description of the experimental therapies.
Similar content being viewed by others
References
Diagnostic and statistical manual of mental disorders fourth edition. DSM-IV. Washington, DC: American Psychiatric Association, 1994
Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006; 43 Suppl. 4: S173–7
World Health Organization. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO Press, 2009
Substance Abuse and Mental Health Services Association. Results from the 2009 National Survey on Drug Use and Health, Rockville (MD): Department of Health and Human Services, 2009
Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002; 137(8): 688–92
Cami J, Farre M. Drug addiction. N Engl J Med 2003; 349(10): 975–86
Nestler EJ. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 1997; 7(5): 713–9
Nestler EJ, Bergson CM, Gultart X, et al. Regulation of neural gene expression in opiate and cocaine addiction. NIDA Res Monogr 1993; 125: 92–116
Kosten TR, O’Connor PG. Management of drug and alcohol withdrawal. N Engl J Med 2003; 348(18): 1786–95
O’Connor PG. Methods of detoxification and their role in treating patients with opioid dependence. JAMA 2005; 294(8): 961–3
Amato L, Minozzi S, Davoli M, et al. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database System Rev 2004; (4): CD005031
Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquire Immune Defic Syndr 1993; 6(9): 1049–56
Metzger DS, Woody GE, O’Brien CP. Drug treatment as HIV prevention: a research update. J Acquire Immune Defic Syndr 2010; 55 Suppl. 1: S32–6
Sullivan LE, Moore BA, Chawarski MC, et al. Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. J Substance Abuse Treat 2008; 35(1): 87–92
Lobmaier P, Gossop M, Waal H, et al. The pharmacological treatment of opioid addiction: a clinical perspective. Eur J Clin Pharmacol 2010; 66(6): 537–45
McLellan AT, Arndt IO, Metzger DS, et al. The effects of psychosocial services in substance abuse treatment. JAMA 1993; 269(15): 1953–9
Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011 Oct 5; (10): CD004147
Stine SM, Kosten TR. Pharmacologic interventions for opioid dependence, in principles of addiction medicine. 4th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2010: 651–69
Dole VP. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 646–50
Dole VP. Narcotic addiction, physical dependence and relapse. N Engl J Med 1972; 286(18): 988–92
Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med 1966; 118(4): 304–9
Dole VP. Implications of methadone maintenance for theories of narcotic addiction. JAMA 1988; 260(20): 3025–9
Dole VP, Nyswander ME, Warner A. Successful treatment of 750 criminal addicts. JAMA 1968; 206(12): 2708–11
Strain EC, Stitzer ML, Liebson IA, et al. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119(1): 23–7
Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag, 1991
Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009; (3): CD002209
Hubbard RL, Craddock SG, Anderson J. Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Substance Abuse Treat 2003; 25(3): 125–34
Strain EC, Bigelow GE, Liebson IA, et al. Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA 1999; 281(11): 1000–5
Donny EC, Brasser SM, Bigelow GE, et al. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005; 100(10): 1496–509
Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2009; 32(2): 131–9
Kim TW, Alford DP, Malabanan A, et al. Low bone density in patients receiving methadone maintenance treatment. Drug Alcohol Depend 2006; 85(3): 258–62
Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009; 150(6): 387–95
Gourevitch MN. First do no harm … reduction? Ann Intern Med 2009; 150(6): 417–8
Anchersen K, Clausen T, Gossop M, et al. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 2009; 104(6): 993–9
Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000; 95(12): 1771–83
Lucas AC, Bermejo AM, Tabernero MJ, et al. Influence of concomitant drugs on methadone elimination half-life in patients under a maintenance treatment. Addict Biol 2001; 6(2): 171–6
Eap CB, Bourquin M, Martin J, et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61(1): 47–54
McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010; 19(1): 4–16
Bickel WK, Amass L. Buprenorphine treatment of opioid dependence: a review. Exper Clin Psychopharmacol 1995; 3: 477–89
Ling W, Charuvastra C, Collins JF, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 1998; 93(4): 475–86
Drug Addiction Treatment Act of 2000, Pub. L. No. 106-310, Title XXXV, sections 3501–3502 (2000)
Vicknasingam B, Mazlan M, Schottenfeld RS, et al. Injection of buprenorphine and buprenorphine/naloxone tablets in Malaysia. Drug Alcohol Depend 2010; 111(1–2): 44–9
Alho H, Sinclair D, Vuori E, et al. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007; 88(1): 75–8
Mendelson J, Jones RT, Welm S, et al. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology 1999; 141(1): 37–46
Harris DS, Mendelson JE, Lin ET, et al. Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone: lack of dose proportionality. Clin Pharmacokinet 2004; 43(5): 329–40
Mendelson J, Jones RT. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4: 1 ratio for treatment? Drug Alcohol Depend 2003; 70 (2 Suppl.): S29–37
Comer SD, Sullivan MA, Vosburg SK, et al. Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers [published erratum appears in Addiction 2010 Jul; 105 (7): 1332]. Addiction 2010; 105(4): 709–18
Fudala PJ, Jaffe JH, Dax EM, et al. Use of buprenorphine in the treatment of opioid addiction, II: physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin Pharmacol Ther 1990; 47(4): 525–34
Amass L, Bickel WK, Higgins ST, et al. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54(17): 1215–28
Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267(20): 2750–5
Amass L, Kamien JB, Branstetter SA. A controlled comparison of the buprenorphine-naloxone tablet and methadone for opioid maintenance treatment: interim results. In: Harris L, editor. Problems of drug dependence 1999 (NIDA research monograph). Rockville (MD): National Institute on Drug Abuse, 2001
Strain EC, Stitzer ML, Liebson IA, et al. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151(7): 1025–30
Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996; 16(1): 58–67
Sohler NL, Li X, Kunins HV, et al. Homeversus office-based buprenorphine inductions for opioid-dependent patients. J Substance Abuse Treat 2010; 38(2): 153–9
Tetrault JM, Sullivan LE, Fiellin DA. Medical management. In: Renner JA, Levonuis P, editors. Handbook of office-based buprenorphine treatment of opioid dependence. Washington, DC: American Psychiatric Publishing, Inc., 2011
Petry NM, Bickel WK, Piasecki D, et al. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9(3): 265–9
Bruce RD, Altice FL. Case series on the safe use of buprenorphine/naloxone in individuals with acute hepatitis C infection and abnormal hepatic liver transaminases. Am J Drug Alcohol Abuse 2007; 33(6): 869–74
Vergara-Rodriguez P, Tozzi M, Botsko M, et al., BHIVES Collaborative. Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquire Immune Defic Syndr 2011; 56 Suppl. 1: S62–7
Wedam EF, Bigelow GE, Johnson RE, et al. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med 2007; 167(22): 2469–75
Reynaud M, Petit G, Potard D, et al. Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998; 93(9): 1385–92
McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91(2–3): 269–78
Deamer RL, Wilson DR, Clark DS, et al. Torsades de pointes associated with high dose levomethadyl acetate (ORLAAM). J Addict Dis 2001; 20(4): 7–14
Ritter AJ, Lintzeris N, Clark N, et al. A randomized trial comparing levo-alpha acetylmethadol with methadone maintenance for patients in primary care settings in Australia. Addiction 2003; 98(11): 1605–13
Wolstein J, Gastpar M, Finkbeiner T, et al. A randomized, open-label trial comparing methadone and levo-alpha-acetylmethadol (LAAM) in maintenance treatment of opioid addiction. Pharmacopsychiatry 2009; 42(1): 1–8
Wieneke H, Conrads H, Wolstein J, et al. Levo-alpha-acetylmethadol (LAAM) induced QTc-prolongation: results from a controlled clinical trial. Eur J Med Res 2009; 14(1): 7–12
Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? NIDA Res Monogr 1995; 150: 37–52
Kleber HD. Naltrexone. J Subst Abuse Treat 1985; 2(2): 117–22
Warner EA, Kosten TR, O’Connor PG. Pharmacotherapy for opioid and cocaine abuse. Med Clin North Am 1997; 81(4): 909–25
Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database of Systematic Reviews 2011; (4): CD001333
Fram DH, Marmo J, Holden R. Naltrexone treatment: the problem of patient acceptance. J Subst Abuse Treat 1989; 6(2): 119–22
Greenstein RA, Arndt IC, McLellan AT, et al. Naltrexone: a clinical perspective. J Clin Psychiatry 1984; 45 (9 Pt 2): 25–8
Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984; 45 (9 Pt 2): 46–8
Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry 2001; 58(8): 755–61
Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict 2006; 15(2): 150–9
Kosten TR, Kleber HD. Strategies to improve compliance with narcotic antagonists. Am J Drug Alcohol Abuse 1984; 10(2): 249–66
McCann MJ, Miotto K, Rawson RA, et al. Outpatient non-opioid detoxification for opioid withdrawal: who is likely to benefit? Am J Addict 1997; 6(3): 218–23
Farren CK, O’Malley SS, Rounsaville B. New treatments for opiate dependence. In: Stine SM, Kosten TR, editors. The Guilford substance abuse series. New York: Guilford Press, 1997: 104–23
Thomson Reuters (Healthcare) Inc. Micromedex® healthcare series. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2009
Thomson Reuters (Healthcare) Inc. DRUGDEX® system 2009. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc., 2009
Tetrault JM, Tate JP, McGinnis KA, et al. Hepatic safety and antiretroviral effectiveness in HIV-infected patients receiving naltrexone. Alcohol Clin Exper Res. Epub 2011 Jul 28
Lobmaier P, Kornør H, Kunøe N, et al. Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2008; (2): CD006140
Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63(2): 210–8
Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377(9776): 1506–13
Kunøe N, Lobmaier P, Vederhus JK, et al. Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 2009; 194(6): 541–6
Kunøe N, Lobmaier P, Vederhus JK, et al. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend 2010; 111(1–2): 166–9
Krupitsky EM, Blokhina EA. Long-acting depot formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010; 23(3): 210–4
Ling W, Casadonte P, Bigelow G, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304(14): 1576–83
Ferri M, Davoli M, Perucci CA. Heroin maintenance for chronic heroin-dependent individuals. Cochrane Database Syst Rev 2010; (8): CD003410
Acknowledgements
Dr Fiellin has received honoraria from Pinney Associates and ParagonRx for serving on External Advisory Boards monitoring the abuse and diversion of buprenorphine. He is supported by DA020576, DA025991, DA026414, P30MH062294, AA018923, HD062080, U79TI020253 and U10 AA13566.
Dr Tetrault is supported by U79TI020253 and DA020576.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tetrault, J.M., Fiellin, D.A. Current and Potential Pharmacological Treatment Options for Maintenance Therapy in Opioid-Dependent Individuals. Drugs 72, 217–228 (2012). https://doi.org/10.2165/11597520-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11597520-000000000-00000